Literature DB >> 26207249

Current trends in the surgical management and treatment of adult glioblastoma.

Richard M Young1, Aria Jamshidi1, Gregory Davis1, Jonathan H Sherman1.   

Abstract

This manuscript discusses the current surgical management of glioblastoma. This paper highlights the common pathophysiology attributes of glioblastoma, surgical options for diagnosis/treatment, current thoughts of extent of resection (EOR) of tumor, and post-operative (neo)adjuvant treatment. Glioblastoma is not a disease that can be cured with surgery alone, however safely performed maximal surgical resection is shown to significantly increase progression free and overall survival while maximizing quality of life. Upon invariable tumor recurrence, re-resection also is shown to impact survival in a select group of patients. As adjuvant therapy continues to improve survival, the role of surgical resection in the treatment of glioblastoma looks to be further defined.

Entities:  

Keywords:  Glioblastoma; neoplasm; neurosurgery; surgical resection; therapeutics

Year:  2015        PMID: 26207249      PMCID: PMC4481356          DOI: 10.3978/j.issn.2305-5839.2015.05.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  78 in total

1.  Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

Authors:  Kenneth F Hofland; Steinbjørn Hansen; Morten Sorensen; Silke Engelholm; Henrik P Schultz; Aida Muhic; Kirsten Grunnet; Anders Ask; Junia C Costa; Charlotte Kristiansen; Carsten Thomsen; Hans Skovgaard Poulsen; Ulrik Lassen
Journal:  Acta Oncol       Date:  2014-01-23       Impact factor: 4.089

2.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

3.  Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article.

Authors:  Tamara Ius; Miriam Isola; Riccardo Budai; Giada Pauletto; Barbara Tomasino; Luciano Fadiga; Miran Skrap
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 5.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

6.  Signs and symptoms of patients with brain tumors presenting to the emergency department.

Authors:  H Snyder; K Robinson; D Shah; R Brennan; M Handrigan
Journal:  J Emerg Med       Date:  1993 May-Jun       Impact factor: 1.484

7.  ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment.

Authors:  Herbert Stepp; Tobias Beck; Thomas Pongratz; Thomas Meinel; Friedrich-Wilhelm Kreth; Jörg Ch Tonn; Walter Stummer
Journal:  J Environ Pathol Toxicol Oncol       Date:  2007       Impact factor: 3.567

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.

Authors:  Alexandra Deviers; Soléakhéna Ken; Thomas Filleron; Benjamin Rowland; Andrea Laruelo; Isabelle Catalaa; Vincent Lubrano; Pierre Celsis; Isabelle Berry; Giovanni Mogicato; Elizabeth Cohen-Jonathan Moyal; Anne Laprie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-08-04       Impact factor: 7.038

10.  Improving the extent of malignant glioma resection by dual intraoperative visualization approach.

Authors:  Ilker Y Eyüpoglu; Nirjhar Hore; Nic E Savaskan; Peter Grummich; Karl Roessler; Michael Buchfelder; Oliver Ganslandt
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  91 in total

1.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

Review 2.  Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.

Authors:  Maria Protopapa; Anna Zygogianni; Georgios S Stamatakos; Christos Antypas; Christina Armpilia; Nikolaos K Uzunoglu; Vassilis Kouloulias
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

3.  Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.

Authors:  Tiara S Napier; Neha Udayakumar; Aditi H Jani; Yolanda E Hartman; Hailey A Houson; Lindsay Moore; Hope M Amm; Nynke S van den Berg; Anna G Sorace; Jason M Warram
Journal:  Mol Cancer Ther       Date:  2020-06-30       Impact factor: 6.261

4.  Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.

Authors:  Margaret Folaron; Mukund Seshadri
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

5.  Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Authors:  Kayla J Wolf; Joseph Chen; Jason Coombes; Manish K Aghi; Sanjay Kumar
Journal:  Nat Rev Mater       Date:  2019-08-16       Impact factor: 66.308

Review 6.  On glioblastoma and the search for a cure: where do we stand?

Authors:  John Bianco; Chiara Bastiancich; Aleksander Jankovski; Anne des Rieux; Véronique Préat; Fabienne Danhier
Journal:  Cell Mol Life Sci       Date:  2017-02-17       Impact factor: 9.261

7.  MiR-148a inhibits the proliferation and migration of glioblastoma by targeting ITGA9.

Authors:  Tong-Jiang Xu; Peng Qiu; Yu-Bao Zhang; Sheng-Yuan Yu; Guang-Ming Xu; Wei Yang
Journal:  Hum Cell       Date:  2019-09-05       Impact factor: 4.174

Review 8.  From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.

Authors:  A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2018-01-15       Impact factor: 3.405

Review 9.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

10.  Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging.

Authors:  Keith R Thulborn; Aiming Lu; Ian C Atkinson; Mohan Pauliah; Kathryn Beal; Timothy A Chan; Antonio Omuro; Josh Yamada; Michelle S Bradbury
Journal:  Clin Cancer Res       Date:  2018-11-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.